Regression and remodeling of cardiac chambers during follow-up after transcatheter aortic valve replacement
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The publication are distributed under the Creative Commons Attribution-NonCommercial-Non Derivatives 4.0 International license (CC BY-NC-ND 4.0). The rights of the works published in this journal are the property of the author and they are free to distribute and disseminate them, as long as the source is correctly cited, no derivative works are generated and these acts do not have commercial purposes.
Main Article Content
Abstract
The use of transcatheter aortic valves replacement (TAVR) has increased due to the aging and high risk population. Some reports have shown promising results on their hemodynamic performance with adequate morbidity and mortality rates. However, the impact of these bioprostheses on left ventricular mass (LVM) is unknown. The main objective of our study was to analyze LVM regression and ventricular remodeling with theses bioprostheses in real-world patients after TAVR. From January 2010 to December 2011, 61 patients underwent transcatheter aortic valve replacement due to severe aortic stenosis.The demographic and clinical characteristics and hemodynamic, electrocardiographic and echocardiographic parameters were collected and analysed. The results are: we observed statistically significant differences between the preoperative and postoperative values in the electrocardiographic parameters, expressed by the criteria of SokolowLyon, Cornell and their respective duration-voltage products, the size of the interventricular septum showed a decrease of 14mm to 11mm and the indexed ventricular mass showed a decrease expressed in terms of the magnitude of the difference of up to 30 g / m2, that is, it has been reduced from 145.5 g / m2 to 115 g / m2. The conclusions are: ventricular remodeling is favorable in TAVR groups measured by echocardiography and electrical criteria, improving contractility and event-free survival at one year follow-up
References
Agmon, Y., Khanderia, B., y Meissner, I. (2001). Aortic valve sclerosis and aortic atherosclerosis:
different manifestations of the same disease? Journal of the American College of
Cardiology, 38, 827-834.
Alpert, J.S. (2003) Aortic stenosis: a new face for an old disease. Archives of Internal Medicine,
, 1769-1770.
Avanza, P., Pascual, I., Del Valle, R., y Morís, C. (2015). Indicaciones del TAVI. ¿En qué se
basan? Revista Española de Cardiología, 15, 27-35.
Badimon, J.J., Fuster, V., y Chesebro, J.H. (1993). Coronary atherosclerosis: a multifactorial
disease. Circulation, 87(2), 13-16.
Bonow, R. (2007). AUC for the Treatment of Patients with Severe Aortic Stenosis. Journal of the
American College of Cardiology, 70(20), 2566-2598.
Bottini, P.B., Carr, A.A., Prisant, L.M., Flickinger, F.W., Allison, J.D., y Gottdiener, J.S. (1995).
Magnetic resonance imaging compared to echocardiography to asses left ventricular
mass in the hypertensive patient. American Journal of Hypertension, 8, 221-228.
Carabello, B.A. (1999). Aortic sclerosis: a window to the coronary arteries? The England Journal
of Medicine, 341, 193-194.
Cioffi, G., Faggiano, P., Vizzardi, E., Tarantini, L., Cramariuc, D., Gerdts, E., y De Simone, G.
(2011). Prognostic value of inappropriately high left ventricular mass in
asymptomaticsevere aortic stenosis. Heart, 97, 301-307.
González, J.L., Martínez, B., Rivero, O.M., Salgado, A.H., y Díaz, P.J. (2013). Diagnóstico
electrocardiográfico de la Hipertrofia Ventricular Izquierda en pacientes hipertensos.
Utilidad del producto duración por voltaje del QRS. Revista Habanera de Ciencias
Médicas, 12(3), 454-463.
Hill, J.A., Karimi, M., Kutschke, W., Davisson, R.L., Zimmerman, K., y Wang, Z. (2000). Cardiac
hypertrophy is not a required compensatory response to short-term pressure overload.
Circulation, 101(24), 2863-2869.
Kappetein, A.P, Head, S.J, Philippe, G., Piazza, N., Mieghem, N.M., y Van Blackstone, E.H.
(2013). Updated standardized endpoint definitions for transcatheter aortic valve
implantation: The Valve Acade mic Research Consortium-2 consensus document.
European Heart Journal, 33(19), 2403-2418. doi: 10.1093/eurheartj/ehs255.
Markku, K., Heikki, T., y Jyri, L. (2005). Left ventricular hypertrophy in aortic valve stenosis:
preventive or promotive of systolic dysfunction and heart failure? European Heart
Journal, 26, 1790-1796.
Mitchell, C., Rahko, P.S., Blauwet, L.A., Canaday, B., Finstuen, J.A., Foster, M.C., y Horton, K.
(2019). Guidelines for Performing a Comprehensive Transthoracic Echocardiographic
Examination in Adults: Recommendations from the American Society of
Echocardiography. Journal of the American Society of Echocardiography, 32(1), 1-64.
Novaro, G.M., Sachar, R., y Pearce, G.L. (2003). Association between apolipoprotein E alleles and
calcific valvular heart disease. Circulation, 108, 1804-1808.
O’Brien, K.D., Reichenbach, D.D., y Marcovina, S.M. (1996). Apolipoproteins B, (a), and E
accumulate in the morphologically early lesion of degenerative valvular aortic stenosis.
Arteriosclerosis, Thrombosis, and Vascular Biology, 16, 523-532.
Otto, C.M., y O’Brien, K.D. (2001). Why is there discordance between calcific aortic stenosis and
coronary artery disease? Heart, 85, 601-602.
Rayner, J., Coffey, S., Newton, J., y Prendergast, B.D. (2014). Aortic valve disease. International
Journal of Clinical Practice, 68(10), 1209-1215.
Routledge, H.C., y Townend, J.N. (2001). ACE inhibition in aortic stenosis: dangerous medicine
or golden opportunity? Journal Human Hypertension, 15, 659-667.
Schwarz, F., Baumann, P., Manthey, J., Hoffmann, M., Schuler, G., y Mehmel, H.C. (1982). The
effect of aortic valve replacement on survival. Circulation, 66(5), 1105-1110.
Tseng, E.E., Lee, C.A., Cameron, D.E., Stuart, R.S., Greene, P.S., y Sussman, M.S. (1997). Aortic
valve replacement in the elderly. Risk factors and long-term results. Annals of Surgery,
(6), 793-804.
Wierzbicki A., y Shetty C. (1999). Aortic stenosis: an atherosclerotic disease? The Journal of
Heart Valve Disease, 4, 416-423.